Piperacillin/Tazobactam

1999/01/01 by Caroline M. Perry, Anthony Markham · 27 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Antibiotics Pharmacokinetics and Efficacy #Antibiotic Resistance in Bacteria #Nosocomial Infections in ICU

paper · pdf · doi:10.2165/00003495-199957050-00017

Cited by

• Genomic insights and phenotypic characterization of three multidrug resistant <i>Cupriavidus</i> strains from the cystic fibrosis lung
• Reducing empiric piperacillin-tazobactam use for patients with community-acquired intra-abdominal infections
• Population pharmacokinetic analysis of piperacillin in burn patients. [europepmc]
• Bilateral endogenous endophthalmitis caused by vancomycin-resistant Staphylococcus epidermidis in a neonate. [europepmc]
• Management of cluster endophthalmitis does not stop at clinical care. [europepmc]
• Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia. [europepmc]
• Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy. [europepmc]
• An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage. [europepmc]
• Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice. [europepmc]
• Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database. [europepmc]
• Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs. [europepmc]
• Kinetic and Structural Characterization of the First B3 Metallo-β-Lactamase with an Active-Site Glutamic Acid. [europepmc]
• Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. [europepmc]
• Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. [europepmc]
• Adaptive Responses of Pseudomonas aeruginosa to Treatment with Antibiotics. [europepmc]
• Glomerular Function and Urinary Biomarker Changes between Vancomycin and Vancomycin plus Piperacillin-Tazobactam in a Translational Rat Model. [europepmc]
• β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources. [europepmc]
• Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study. [europepmc]
• Antimicrobial Challenge in Acute Care Surgery. [europepmc]
• Biochemical exploration of β-lactamase inhibitors. [europepmc]
• Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database. [europepmc]
• Iohexol-Measured Glomerular Filtration Rate and Urinary Biomarker Changes between Vancomycin and Vancomycin Plus Piperacillin-Tazobactam in a Translational Rat Model. [europepmc]
• Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice. [europepmc]
• Removal of common antimicrobial agents by sustained low-efficiency dialysis. [europepmc]
• Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales . [europepmc]
• Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria. [europepmc]
• The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers. [europepmc]